Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

A drug commonly used to treat arthritis caused a dramatic and rapid improvement in patients with Alzheimer’s disease, according to physicians in California. However, scientists and others not involved in the work worry that the report, which was based on trials in a few patients and hasn’t been independently confirmed, may offer little more than false hope for Alzheimer’s sufferers and their families.

Alzheimer’s patients injected with the anti-inflammatory drug etanercept–marketed as Enbrel–showed dramatic improvements in their functioning within minutes, according to Edward Tobinick, director of the Institute for Neurological Research, a private medical facility in Los Angeles where the patients were treated, and an assistant clinical professor of medicine at the University of California, Los Angeles.

“The patients improve literally before your eyes,” says Tobinick, who began using etanercept in Alzheimer’s patients three years ago. He uses an unconventional method to administer the drug; he injects it near patients’ spines. In 2006, he reported success with weekly treatments given to 15 people over the course of six months. In a case study in the latest issue of the Journal of Neuroinflammation, Tobinick and Hyman Gross, who practices in Santa Monica, describe how a patient improved within 10 minutes of treatment, and how cognitive tests performed two hours after the treatment showed a marked improvement over tests given before the injection. Tobinick says that the rapid improvement is typical in patients he has injected with etanercept. He treats them weekly, or, in some cases, less often.

“In each case, the person was more alert, calm, attentive, and they stayed on track,” says Sue Griffin, director of research at the Donald W. Reynolds Institute on Aging at the University of Arkansas for Medical Sciences, who watched Tobinick treat several patients. Griffin says that she was skeptical when she first heard about Tobinick’s approach, but having witnessed the effect firsthand, she says, “It was just completely amazing, like nothing I’d ever seen for an Alzheimer’s person.”

Minutes before the treatment, the patient in the case study couldn’t recall the year or which state he was in. Ten minutes after the injection, he answered these questions correctly. As part of a cognitive assessment performed the day before the treatment, the patient was asked to draw a clock face showing a certain time. He sketched a square. Two hours after the injection, he drew a round face with two hands in approximately the correct positions.

The case report on this patient’s rapid improvement is “interesting,” says William Thies, vice president of medical and scientific relations for the Alzheimer’s Association, but he adds that “we’re going to need more information before it’s something that people should get wildly excited about.”

“There are some kernels of good science here,” says David Standaert, director of the Center for Neurodegeneration and Experimental Therapeutics at the University of Alabama at Birmingham, but he cautions that “this is not enough evidence that we would start treating people outside of a trial.” Standaert was not involved in the work.

Etanercept has been used since 1998, primarily to treat rheumatoid arthritis. It’s usually injected into the thigh, stomach, or upper arm, but Tobinick says that by injecting it into the neck, near the spine, the drug can reach the brain. It’s a method that requires considerable skill. “It would be incorrect for anyone to think that they could just take Enbrel if they have Alzheimer’s, and they’ll get better,” he says.

5 comments. Share your thoughts »

Credit: Technology Review

Tagged: Biomedicine, drugs, Alzheimer’s

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me